Showing 911-920 of 2876 results for "".
- New From Alma: Alma TED, CBD+ Professional Linehttps://modernaesthetics.com/news/new-from-alma-alma-ted-cbd-professional-line/2473212/Alma TED, an Ultrasound-based system with a propriety Tip engineered with Impact Delivery™, offers a non-invasive, non-traumatic option to address the market's growing hair loss concerns. Alma launched the device, along with the CBD+ Professional S
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Laser Surgery Lawsuits May be Less Likely with Physician Operatorshttps://modernaesthetics.com/news/laser-surgery-lawsuits-may-be-less-likely-with-physician-operators/2473208/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneou
- Newsweek OpEd: Senator, Modern Aesthetics® Magazine Contributor Address "No Surprises Act"https://modernaesthetics.com/news/newsweek-oped-senator-modern-aesthetics-magazine-contributor-address-no-surprises-act/2473207/Although surprise bills are one of the biggest drivers of medical bankruptcy in America, the "No Surprises Act" (NSA) is being overlooked, say Jonathan Kaplan, MD and Sen. William Cassidy, MD (R, Louisiana) in a new
- Endo Launches New Consumer Campaign for Qwohttps://modernaesthetics.com/news/endo-launches-new-consumer-campaign-for-qwo/2473202/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- Galderma Launches Alastin Skincare® ReFORM & RePAIR COMPLEXhttps://modernaesthetics.com/news/galderma-launches-alastin-skincare-reform-repair-complex/2473199/Galderma has launched Alastin Skincare® ReFORM & RePAIR COMPLEX with TriHex Technology®. Designed to be used pre- and post-surgery to create an optimal environment for recovery, ReFORM & RePAIR COMPLEX with TriHex Technology® aims to help accelerate the recovery proc
- Meet Radiesse (+) from Merz: The First and Only Aesthetic Injectable for Jawline Contourhttps://modernaesthetics.com/news/meet-radiesse-from-merz-the-first-and-only-aesthetic-injectable-for-jawline-contour/2473190/Merz Aesthetics is launching Radiesse (+) Lidocaine for jawline contouring in adults over the age of 21. Radiesse (+) is the first and only U.S. Food and Drug Administration (FDA)-approved injectable treatment for jawline contour improvement. The FDA approved the supplemental
- Aesthetics Biomedical Expands Vivace and SoME Skincare Ambassadorship Programhttps://modernaesthetics.com/news/aesthetics-biomedical-expands-vivace-and-some-skincare-ambassadorship-program/2473177/Aesthetics Biomedical Inc. (ABM) has expanded its Vivace & SoME Skincare Ambassadorship Program, which brings notable plastic surgeons, dermatologists, medical aesthetic practitioners, and skincare professionals together with two fast growing aestheti
- Sculptra Gets New Labelhttps://modernaesthetics.com/news/sculptra-gets-new-label/2473175/A new FDA-approved label for Sculptra® (injectable poly-L-lactic acid (PLLA)) from Galderma includes higher dilution, the addition of immediate use reconstitution, new injection techniques, and the optional addition of lidocaine. Sculptra is the first and only FDA-approved PLLA facial in
- Placental Allograft Technology from MiMedx Shown Beneficial for Mohs Repairshttps://modernaesthetics.com/news/placental-allograft-technology-from-mimedx-shown-beneficial-for-mohs-repairs/2473174/MiMedx Group’s Purion® processed dHACM (Epifix®) placental allografts are associated with a statistically significant lower risk for infection, poor scar cosmesis, scar revision, and additional operation at the index site, when compared to traditional methods of incisional repair po